The clinical features of pathologically confirmed vascular Parkinsonism

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 10, 2012, Pages 1027-1029

  Glass, Philip George ^a,b,c   Lees, Andrew J ^a,d   Bacellar, Aroldo ^b   Zijlmans, Jan ^e   Katzenschlager, Regina ^f   Silveira Moriyama, Laura ^a,c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL SÃO RAFAEL   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e AMPHIA HOSPITAL   (Netherlands)

^f DANUBE HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; LEVODOPA;

ADULT; AGED; ARTICLE; BRADYKINESIA; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; DEMENTIA; DISABILITY; DISEASE COURSE; DISEASE DURATION; FALLING; FEMALE; HUMAN; LEWY BODY; MALE; MUSCLE RIGIDITY; ONSET AGE; PARKINSONISM; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; PYRAMIDAL SIGN; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; URINE INCONTINENCE; VASCULAR PARKINSONISM; VISUAL HALLUCINATION;

EID: 84866174381     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302828     Document Type: Article

References (14)

1. Zijlmans JC, Daniel SE, Hughes AJ, et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004;19:630-40.
2. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 1997;28:965-9.
3. Jellinger KA. Vascular parkinsonism - neuropathological findings. Acta Neurol Scand 2002;105:414-15.
4. Kempster PA, O'Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133:1755-62.
5. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131:1362-72.
6. Poggesi A, Pantoni L, Inzitari D, et al. 2001-2011: A decade of the LADIS (Leukoaraiosis and DISability) study: what have we learned about white matter changes and small-vessel disease? Cerebrovasc Dis 2011;32:577-88.
7. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5-12.
8. Foltynie T, Barker R, Brayne C. Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology 2002;21:1-7.
9. Bower JH, Dickson DW, Taylor L, et al. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord 2002;17:910-16.
10. Zijlmans JC, Katzenschlager R, Daniel SE, et al. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004;75:545-7.
11. Forno LS. Reaction of the substantia nigra to massive basal ganglia infarction. Acta Neuropathol 1983;62:96-102.
12. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994;44:437-41.
13. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010;25:149-56.
14. Bohnen NI, Muller ML, Zarzhevsky N, et al. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 2011;134:2358-65.